Filippi et al. [29] showed that treating mice with TLR2 agonists before developing diabetes reduced the likelihood of developing type 1 diabetes by increasing the number of CD4+ CD25+ T cells and imparting tolerogenic properties to DC. Here, TLR2 is linked to diabetes mellitus.